Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Primary Myelofibrosis 24Leukemia, Myeloid, Acute 16Myeloproliferative Disorders 15Polycythemia Vera 12Leukemia 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Myelodysplastic Syndromes 9Thrombocythemia, Essential 8Graft vs Host Disease 8Recurrence 6Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, T-Cell 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Breast Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, T-Cell, Cutaneous 3Leukemia, Prolymphocytic, T-Cell 3Leukemia, Myelomonocytic, Chronic 3Hematologic Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Bronchiolitis Obliterans Syndrome 3Triple Negative Breast Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2

Interventions

asciminib 8Dasatinib 7nilotinib 6Imatinib Mesylate 5Cyclophosphamide 4ponatinib 3fludarabine phosphate 3bosutinib 3Whole-Body Irradiation 3ruxolitinib 2letermovir 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Methotrexate 2Melphalan 2Cyclosporine 2Busulfan 2venetoclax 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1decitabine and cedazuridine drug combination 1Vorinostat 1Valganciclovir 1Tyrosine Kinase Inhibitors 1Therapeutics 1Stem Cell Transplantation 1Sirolimus 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Chronic-Phase × ruxolitinib × 1 year × Clear all
NCT03610971 2026-04-02

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
24 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03654768 2025-12-18

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

SWOG Cancer Research Network

Phase 2 Active not recruiting
81 enrolled 20 charts
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡